Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.31 |
| ▸ | CTSK | P43235 | 2/20 | 0.31 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20533115 | 1.00 | ACLY (0.43) | ACLYTSHRALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL132112 | 1.00 | ACLY (0.43) | ACLYTSHRALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL23217911 | 0.87 | ACLY (0.48) | ACLYTSHRALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL23217912 | 0.87 | ACLY (0.48) | ACLYTSHRALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL6325253 | 0.84 | ACLY (0.39) | ACLYTSHRALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL6450507 | 0.80 | TSHR (0.35) | ACLYTSHRALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL27534724 | 0.78 | PPARG (0.48) | ACLYALDH1A1CYP2C19 | |
| SCHEMBL11857840 | 0.77 | GRIK1 (0.32) | ACLYTSHRALDH1A1GRIK1GRIK2 | |
| SCHEMBL11857824 | 0.77 | GRIK1 (0.32) | ACLYTSHRALDH1A1GRIK1GRIK2 | |
| SCHEMBL9049415 | 0.76 | TSHR (0.41) | ACLYTSHRALDH1A1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503422-B2 | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor | NEUROBO PHARMACEUTICALS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| EP-4219008-B1 | USE FOR THE TREATMENT OF AN ION EXCHANGE RESIN | MITSUBISHI CHEMICAL UK LTD (GB) | 2024-11-20 | — | — | EP | disclosed |
| EP-4049754-B1 | PROCESS FOR THE TREATMENT OF AN ION EXCHANGE RESIN | MITSUBISHI CHEMICAL UK LTD (GB) | 2024-04-03 | — | — | EP | disclosed |
| EP-4219008-A1 | USE FOR THE TREATMENT OF AN ION EXCHANGE RESIN | Mitsubishi Chemical UK Limited (GB) | 2023-08-02 | — | — | EP | disclosed |
| EP-3862085-B1 | PROCESS FOR THE TREATMENT OF AN ION EXCHANGE RESIN | MITSUBISHI CHEMICAL UK LTD (GB) | 2023-06-07 | — | — | EP | disclosed |
| US-20220332672-A1 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | NEUROBO PHARMACEUTICALS INC (US) | 2022-10-20 | — | — | US | disclosed |
| EP-4049754-A1 | PROCESS FOR THE TREATMENT OF AN ION EXCHANGE RESIN | Mitsubishi Chemical UK Limited (GB) | 2022-08-31 | — | — | EP | disclosed |
| EP-2411147-B1 | PROCESS FOR THE TREATMENT OF AN ION EXCHANGE RESIN | MITSUBISHI CHEMICAL UK LTD (GB) | 2022-04-20 | — | — | EP | disclosed |
| CN-113396138-A | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof, and methods of use thereof | 燿石治疗公司 | 2021-09-14 | — | — | CN | disclosed |
| EP-3862085-A1 | PROCESS FOR THE TREATMENT OF AN ION EXCHANGE RESIN | Mitsubishi Chemical UK Limited (GB) | 2021-08-11 | — | — | EP | disclosed |
| EP-3612171-A1 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | Gemphire Therapeutics Inc. (US) | 2020-02-26 | — | — | EP | disclosed |
| WO-2018195163-A1 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | GEMPHIRE THERAPEUTICS INC. (US) | 2018-10-25 | — | — | WO | disclosed |
| US-20180297929-A1 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | NEUROBO PHARMACEUTICALS, INC. | 2018-10-18 | — | — | US | disclosed |
| US-9821304-B2 | Process for the treatment of an ion exchange resin | LUCITE INTERNATIONAL UK LIMITED (GB) | 2017-11-21 | — | — | US | disclosed |
| US-20140343176-A1 | PROCESS FOR THE TREATMENT OF AN ION EXCHANGE RESIN | Mitsubishi Chemical UK Limited (GB) | 2014-11-20 | — | — | US | disclosed |
| US-8835518-B2 | Process for the treatment of an ion exchange resin | LUCITE INTERNATIONAL UK LIMITED (GB) | 2014-09-16 | — | — | US | disclosed |
| US-20120059073-A1 | PROCESS FOR THE TREATMENT OF AN ION EXCHANGE RESIN | LUCITE INTERNATIONAL UK LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| EP-2411147-A2 | PROCESS FOR THE TREATMENT OF AN ION EXCHANGE RESIN | Lucite International UK Limited (GB) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010109244-A2 | PROCESS FOR THE TREATMENT OF AN ION EXCHANGE RESIN | LUCITE INTERNATIONAL UK LIMITED (GB) | 2010-09-30 | — | — | WO | disclosed |
| WO-2007007084-A2 | COPPER (II) CATALYSED ADDITIONS TO ALKENES | IC INNOVATIONS LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332672-A1 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | NPC1L1, NOTUM, CEL | ACLY 2298/4885TSHR 4388/4885ALDH1A1 1952/4885 |
| US-20120059073-A1 | PROCESS FOR THE TREATMENT OF AN ION EXCHANGE RESIN | RCOR1, RER1, DECR1 | ACLY 1136/4885TSHR 2640/4885ALDH1A1 342/4885 |
| US-12503422-B2 | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor | NPC1L1, NOTUM, CEL | ACLY 2298/4885TSHR 4388/4885ALDH1A1 1952/4885 |
| US-20180297929-A1 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | NPC1L1, NOTUM, CEL | ACLY 2298/4885TSHR 4388/4885ALDH1A1 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.